John S Tyhonas (John Tyhonas)

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 8

Top Topics

Tyrosine Kinase

End Stage Renal Disease

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Journal of medicinal chemistry

This page only lists publications with an associated author ORCID identifier.

Publications

John S Tyhonas, Lee D Arnold, Jason M Cox, Aleksandra Franovic, Elisabeth Gardiner, Kathryn Grandinetti, Robert Kania, Toufike Kanouni, Matthew Lardy, Chun Li, Eric S Martin, Nichol Miller, Adithi Mohan, Eric A Murphy, Michelle Perez, Liliana Soroceanu, Noel Timple, Sean Uryu, Scott Womble, Stephen W Kaldor
Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations. Journal of medicinal chemistry (2024)
Eranga Roshan Balasooriya, Qibiao Wu, Haley Ellis, Yuanli Zhen, Bryanna L Norden, Ryan B Corcoran, Adithi Mohan, Eric Martin, Aleksandra Franovic, John S Tyhonas, Matthew Lardy, Kathryn B Grandinetti, Robert Pelham, Liliana Soroceanu, Vanessa Silva Silveira, Nabeel El-Bardeesy
The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (10) (2024)
Eranga Roshan Balasooriya, Qibiao Wu, Haley Ellis, Yuanli Zhen, Bryanna L Norden, Ryan B Corcoran, Adithi Mohan, Eric Martin, Aleksandra Franovic, John S Tyhonas, Matthew Lardy, Kathryn B Grandinetti, Robert Pelham, Liliana Soroceanu, Vanessa Silva Silveira, Nabeel El-Bardeesy
The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (10) (2024)
Eranga Roshan Balasooriya, Qibiao Wu, Haley Ellis, Yuanli Zhen, Bryanna L Norden, Ryan B Corcoran, Adithi Mohan, Eric Martin, Aleksandra Franovic, John S Tyhonas, Matthew Lardy, Kathryn B Grandinetti, Robert Pelham, Liliana Soroceanu, Vanessa Silva Silveira, Nabeel El-Bardeesy
The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (10) (2024)
John S Tyhonas, Lee D Arnold, Jason M Cox, Aleksandra Franovic, Elisabeth Gardiner, Kathryn Grandinetti, Robert Kania, Toufike Kanouni, Matthew Lardy, Chun Li, Eric S Martin, Nichol Miller, Adithi Mohan, Eric A Murphy, Michelle Perez, Liliana Soroceanu, Noel Timple, Sean Uryu, Scott Womble, Stephen W Kaldor
Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations. Journal of medicinal chemistry 67 (3) (2024)
Eranga Roshan Balasooriya, Qibiao Wu, Haley Ellis, Yuanli Zhen, Bryanna L Norden, Ryan B Corcoran, Adithi Mohan, Eric Martin, Aleksandra Franovic, John S Tyhonas, Matthew Lardy, Kathryn B Grandinetti, Robert Pelham, Liliana Soroceanu, Vanessa Silva Silveira, Nabeel El-Bardeesy
The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (10) (2024)
John S Tyhonas, Lee D Arnold, Jason M Cox, Aleksandra Franovic, Elisabeth Gardiner, Kathryn Grandinetti, Robert Kania, Toufike Kanouni, Matthew Lardy, Chun Li, Eric S Martin, Nichol Miller, Adithi Mohan, Eric A Murphy, Michelle Perez, Liliana Soroceanu, Noel Timple, Sean Uryu, Scott Womble, Stephen W Kaldor
Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations. Journal of medicinal chemistry 67 (3) (2024)
Eranga Roshan Balasooriya, Qibiao Wu, Haley Ellis, Yuanli Zhen, Bryanna L Norden, Ryan B Corcoran, Adithi Mohan, Eric Martin, Aleksandra Franovic, John S Tyhonas, Matthew Lardy, Kathryn B Grandinetti, Robert Pelham, Liliana Soroceanu, Vanessa Silva Silveira, Nabeel El-Bardeesy
The irreversible FGFR inhibitor KIN-3248 overcomes FGFR2 kinase domain mutations. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)